Company patents
AUTOLUS LIMITED
AUTOLUS LIMITED's patent strategy is heavily concentrated in core pharma_biotech areas, with Pharmaceutical Preparations (80.7% of portfolio) and Peptides & Proteins (73.9%) dominating, despite a notable decline in filings so far in 2026 for both categories. Surprisingly, the company appears to be significantly deprioritizing non-core areas, with Material & Chemical Analysis, Genetic & Microbiological Assays, and Healthcare Informatics all showing a 100.0% decline in filings in 2026 compared to 2025, indicating a sharp focus shift away from these sectors.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
88 US filings (since 2023) · 6 categories · 8 themes
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Patents
Showing 1-4 of 4
Protein & Peptide Engineering